Literature DB >> 23698004

Clinical characteristics of patients with resistant hypertension: the RESIST-POL study.

E Florczak1, A Prejbisz, E Szwench-Pietrasz, P Sliwiński, P Bieleń, A Klisiewicz, I Michałowska, E Warchoł, M Januszewicz, M Kała, A Witkowski, A Więcek, K Narkiewicz, V K Somers, A Januszewicz.   

Abstract

Recent studies indicate that resistant hypertension (RHTN) is present in about 12% of the treated hypertensive population. However, patients with true RHTN (confirmed out of the office) have not been widely studied. We prospectively studied 204 patients (123 male, 81 female, mean age 48.4 years, range 19-65 years) with truly RHTN (ambulatory daytime mean blood pressure >135/85 mm  Hg). We evaluated the frequency of obstructive sleep apnea (OSA), renal artery stenosis (RAS), primary aldosteronism (PA) and other secondary forms of hypertension (HTN) and conditions. Mild, moderate and severe OSA were present in 55 (27.0%), 38 (18.6%) and 54 (26.5%) patients, respectively. Secondary forms of HTN were diagnosed in 49 patients (24.0%), the most frequent being PA (15.7%) and RAS (5.4%). Metabolic syndrome (MS) was present in 65.7% of patients. Excessive sodium excretion was evident in 33.3% of patients and depression in 36.8% patients. In patients with RHTN, OSA and MS were the most frequent conditions, frequently overlapping with each other and also with PA. Our data indicate that in the vast majority of patients with truly RHTN, at least one of three co-morbidities-OSA, MS and PA-is present. Other conditions, even though less frequent, should also be taken into the consideration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23698004     DOI: 10.1038/jhh.2013.32

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  28 in total

1.  Obesity, Hypoxemia, and Hypertension: Mechanistic Insights and Therapeutic Implications.

Authors:  Allyn L Mark; Virend K Somers
Journal:  Hypertension       Date:  2016-05-09       Impact factor: 10.190

2.  Potential effects of age on screening for primary aldosteronism.

Authors:  Q Luo; N F Li; X G Yao; D L Zhang; S F Y Abulikemu; G J Chang; K M Zhou; G L Wang; M H Wang; W J Ouyang; Q Y Cheng; Y Jia
Journal:  J Hum Hypertens       Date:  2015-04-16       Impact factor: 3.012

3.  Advances in resistant hypertension.

Authors:  David A Calhoun
Journal:  Ann Transl Med       Date:  2018-08

4.  Renal nerves: time for reassessment of their role in hypertension?

Authors:  Gregory D Fink; John W Osborn
Journal:  Am J Hypertens       Date:  2014-05-28       Impact factor: 2.689

5.  Determinants of concentric left ventricular hypertrophy in patients with resistant hypertension: RESIST-POL study.

Authors:  Piotr Dobrowolski; Aleksander Prejbisz; Anna Klisiewicz; Elżbieta Florczak; Justyna Rybicka; Andrzej Januszewicz; Piotr Hoffman
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

Review 6.  Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Authors:  Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-18       Impact factor: 3.872

7.  Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Authors:  Tanja Dudenbostel; Lama Ghazi; Mingchun Liu; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

8.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 9.  Resistant Hypertension Updated Guidelines.

Authors:  Irene Chernova; Namrata Krishnan
Journal:  Curr Cardiol Rep       Date:  2019-08-30       Impact factor: 2.931

10.  Brazilian Position Statement on Resistant Hypertension - 2020.

Authors:  Juan Carlos Yugar-Toledo; Heitor Moreno Júnior; Miguel Gus; Guido Bernardo Aranha Rosito; Luiz César Nazário Scala; Elizabeth Silaid Muxfeldt; Alexandre Alessi; Andrea Araújo Brandão; Osni Moreira Filho; Audes Diógenes de Magalhães Feitosa; Oswaldo Passarelli Júnior; Dilma do Socorro Moraes de Souza; Celso Amodeo; Weimar Kunz Sebba Barroso; Marco Antônio Mota Gomes; Annelise Machado Gomes de Paiva; Eduardo Costa Duarte Barbosa; Roberto Dischinger Miranda; José Fernando Vilela-Martin; Wilson Nadruz Júnior; Cibele Isaac Saad Rodrigues; Luciano Ferreira Drager; Luiz Aparecido Bortolotto; Fernanda Marciano Consolim-Colombo; Márcio Gonçalves de Sousa; Flávio Antonio de Oliveira Borelli; Sérgio Emanuel Kaiser; Gil Fernando Salles; Maria de Fátima de Azevedo; Lucélia Batista Neves Cunha Magalhães; Rui Manoel Dos Santos Póvoa; Marcus Vinícius Bolívar Malachias; Armando da Rocha Nogueira; Paulo César Brandão Veiga Jardim; Thiago de Souza Veiga Jardim
Journal:  Arq Bras Cardiol       Date:  2020 May-Jun       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.